Wall Street's Insights Into Key Metrics Ahead of Amneal (AMRX) Q2 EarningsZacks Investment Research • 08/07/24
Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to DeclineZacks Investment Research • 08/02/24
Amneal Pharmaceuticals (AMRX) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 07/29/24
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab BiosimilarBusiness Wire • 07/01/24
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)Business Wire • 07/01/24
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New TherapiesBusiness Wire • 06/05/24
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of CaliforniaBusiness Wire • 05/22/24
Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/03/24
Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?Zacks Investment Research • 04/25/24
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseBusiness Wire • 04/24/24
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineBusiness Wire • 04/16/24
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionBusiness Wire • 03/25/24